Mario Campone

Research interests

Publications

• Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00694-5

• Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-020-01189-2

• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.015

• Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.05.001

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30863-0

• Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.11.011

• Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30812-x

• Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1813904

• Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

  British Journal of Cancer · 2019 · https://doi.org/10.1038/s41416-019-0619-y

• Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy155

• Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30716-7

• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.6155

• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30376-5

• Lomustine and Bevacizumab in Progressive Glioblastoma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1707358

• Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

  PLoS Medicine · 2016 · https://doi.org/10.1371/journal.pmed.1002201

• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1609709

• Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00188-6

• Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1413513

• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu456

• Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(13)70611-9

• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70130-x

• Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.2464

• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  Clinical Cancer Research · 2013 · https://doi.org/10.1158/1078-0432.ccr-13-0190

• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2011 · 10.1056/nejmoa1109653

Current projects

No projects listed.